var data={"title":"Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/228134?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information\" class=\"drug drug_general\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Drug information&quot;</a> and <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-patient-drug-information\" class=\"drug drug_patient\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000299\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alphanate ;</li>\n      <li>Humate-P;</li>\n      <li>Wilate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663155\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Humate-P;</li>\n      <li>Wilate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958727\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958736\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information\" class=\"drug drug_general\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A (Factor VIII deficiency): </b>\n      <b>Note:</b> Dosage and duration of treatment must be individualized based on the severity of factor VIII deficiency, extent and location of bleeding, presence of inhibitors and clinical status of patient. Titrate the dose as needed based on clinical response; whenever possible, perform serial FVIII activity assays to assess clinical response. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <span style=\"text-decoration: underline\">Hemorrhage, treatment:</span> Infants, Children, and Adolescents: IV: <b>Note:</b> Factor VIII concentrations may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose. Guidelines do not specify a preferred agent; see product specific information for approved ages and uses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>General dosing recommendations:</i> The following recommendations reflect general dosing requirements; may vary from those found within prescribing information or practitioner preference (WFH [Srivastav 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In general, administration of 1 unit/kg of factor VIII will increase circulating factor VIII concentrations by ~2 units/dL (or 2%); calculated dosage should be adjusted to the actual vial size. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Formula to calculate dosage required is based on desired increase in factor VIII (% of normal); <b>Note:</b> This formula assumes that the patient's baseline AHF level is &lt;1%: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose (units) = Body weight (kg) x 0.5 x desired factor VIII increase (units/dL or % of normal) </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Desired Factor VIII Concentration to Maintain and Duration Based on Site of Hemorrhage/Clinical Situation (when no significant resource constraints exist) (WFH [Srivastava 2013])</caption>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <tbody>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Joint</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL for 1 to 2 days, may be longer if response is inadequate </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Superficial muscle (no neurovascular compromise)</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL for 2 to 3 days, sometimes longer if response is inadequate </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Initial: 80 to 100 units/dL for 1 to 2 days</p>\n            <p style=\"text-indent:0em;\">Maintenance: 30 to 60 units/dL for 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">CNS/head</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Initial: 80 to 100 units/dL for 1 to 7 days</p>\n            <p style=\"text-indent:0em;\">Maintenance: 50 units/dL for 8 to 21 days </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Throat and neck</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Initial: 80 to 100 units/dL for 1 to 7 days</p>\n            <p style=\"text-indent:0em;\">Maintenance: 50 units/dL for 8 to 14 days </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Gastrointestinal</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Initial: 80 to 100 units/dL for 7 to 14 days </p>\n            <p style=\"text-indent:0em;\">Maintenance: 50 units/dL (duration not specified) </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Renal</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">50 units/dL for 3 to 5 days </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Deep laceration</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">50 units/dL for 5 to 7 days </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Surgery (major): </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;margin-top:6em;\">Preoperative: 80 to 100 units/dL</p>\n            <p style=\"text-indent:0em;margin-top:2em;\">Postoperative: 60 to 80 units/dL for postop days 1 to 3, then 40 to 60 units/dL for postop days 4 to 6, then 30 to 50 units/dL for postop days 7 to 14 </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Surgery (minor):</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;margin-top:2em;\">Preoperative: 50 to 80 units/dL</p>\n            <p style=\"text-indent:0em;margin-top:2em;\">Postoperative: 30 to 80 units/dL for 1 to 5 days depending on procedure type</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Product-specific dosing:</i> Alphanate: Children &ge;7 years and Adolescents: IV: <b>Note:</b> In general, administration of Alphanate FVIII:C 1 unit/kg will increase the plasma FVIII:C activity by ~2 units/dL (or 2% of normal), as demonstrated by the following formulas: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage (units) based on desired increase in factor VIII (units/dL or % normal): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage (units) = Body Weight (kg) x 0.5 (units/kg per units/dL) x desired factor VIII increase (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minor hemorrhage (large bruises; significant cuts or scrapes; uncomplicated joint hemorrhage): FVIII:C 15 units/kg/dose twice daily to achieve FVIII:C concentration 30% of normal. Continue until hemorrhage stops and healing has been achieved (1 to 2 days).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate hemorrhage (nose, mouth, and gum bleeds; dental extractions; hematuria): FVIII:C 25 units/kg/dose twice daily to achieve FVIII:C concentration 50% of normal. Continue treatment until healing has been achieved (2 to 7 days, on average).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major hemorrhage (joint hemorrhage; muscle hemorrhage; major trauma; hematuria; intracranial and intraperitoneal bleeding): FVIII:C 40 to 50 units/kg/dose twice daily to achieve FVIII:C concentrations 80% to 100% of normal for at least 3 to 5 days; followed by FVIII:C 25 units/kg/dose twice daily to maintain FVIII:C concentrations at 50% of normal until healing has been achieved. Major hemorrhages may require treatment for up to 10 days. Intracranial hemorrhage may require prophylactic therapy for up to 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Surgery: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preoperative: FVIII:C 40 to 50 units/kg to achieve FVIII:C concentrations 80% to 100% of normal </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postoperative: FVIII:C 30 to 50 units/kg/dose twice daily to maintain FVIII:C concentrations at 60% to 100% of normal for the next 7 to 10 days or until healing has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <span style=\"text-decoration: underline\">Prophylaxis, primary:</span> Limited data available; multiple protocols exist; optimum regimen has yet to be defined: Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Utrecht protocol: 15 to 30 units/kg/dose 3 times weekly (WFH [Srivastava 2013]) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malm&ouml; protocol: 25 to 40 units/kg/dose 3 times weekly (WFH [Srivastava 2013]) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MASAC recommendations: 25 to 50 units/kg/dose 3 times weekly or every other day (National Hemophilia Foundation, MASAC recommendation 2007) </p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>von Willebrand disease (VWD), treatment:</b> <b>Dosage is expressed in international units of von Willebrand factor: Ristocetin cofactor (VWF:RCo):</b> Dose must be individualized based on type of VWD, extent and location of bleeding, clinical status of patient, and coagulation studies performed prior to and at regular intervals during treatment. For major bleeds where repeated dosing is required, monitor and maintain the FVIII plasma concentration as described for the treatment of hemophilia A. Products are not identical and should not be used interchangeably (NHLBI 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <span style=\"text-decoration: underline\">Hemorrhage, treatment:</span> Product-specific dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humate P:</i> Infants, Children, and Adolescents: IV: <b>Note:</b> In general, administration of 1 unit/kg of factor VIII would be expected to raise circulating VWF:RCo ~5 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">General dosing: VWF:RCo 40 to 80 units/kg/dose every 8 to 12 hours; adjust based on extent and location of hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on Von Willebrand type and hemorrhage severity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Type 1, mild VWD (baseline VWF:RCo activity typically &gt;30%): Minor hemorrhage (if desmopressin is not appropriate) or major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, traumatic hemorrhage): </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: VWF:RCo 40 to 60 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: VWF:RCo 40 to 50 units/kg/dose every 8 to 12 hours for 3 days, maintain VWF:RCo nadir &gt;50%; follow with VWF:RCo 40 to 50 units/kg/dose once daily for up to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Type 1, moderate or severe VWD (baseline VWF:RCo activity typically &lt;30%): </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia): VWF:RCo 40 to 50 units/kg/dose for 1 to 2 doses </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo 50 to 75 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg/dose every 8 to 12 hours for 3 days; maintain VWF:RCo nadir &gt;50%; follow with VWF:RCo 40 to 60 units/kg/dose once daily for up to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Types 2 (all variants) and 3 VWD: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia): VWF:RCo 40 to 50 units/kg/dose for 1 to 2 doses </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo 60 to 80 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg/dose every 8 to 12 hours for 3 days, maintain VWF:RCo nadir &gt;50%; follow with 40 to 60 units/kg/dose once daily for up to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Wilate:</i> Children &ge;5 years and Adolescents: IV: <b>Note:</b> Patients with Type 3 VWD and those with GI bleeding may require higher doses. In general, administration of VWF:RCo 1 unit/kg will increase the plasma VWF activity by ~2 units/dL (or 2% of normal), as demonstrated by the following formulas: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage (units) based on desired factor VWF:RCo increase (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage (units) = Body weight (kg) x 0.5 (units/kg per units/dL) x desired VWF:RCo increase (units/dL or % normal) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minor hemorrhage: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo 20 to 40 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: VWF:RCo 20 to 30 units/kg/dose every 12 to 24 hours for &le;3 days, keeping the nadir of VWF:RCo and FVIII activity &gt;30% </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major hemorrhage: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo 40 to 60 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: VWF:RCo 20 to 40 units/kg/dose every 12 to 24 hours for 5 to 7 days, keeping the nadir of VWF:RCo and FVIII activity &gt;50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <span style=\"text-decoration: underline\">Prophylaxis, surgical/procedural:</span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alphanate:</i> Children &ge;7 years and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minor surgery/bleeding:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 40 to 50 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 40 to 50 units/dL for 1 to 3 days; do not exceed FVIII:C activity level of 150 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major surgery/bleeding (excluding Type 3 VWD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 100 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 100 units/dL for 3 to 7 days; do not exceed FVIII:C activity level of 150 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humate-P:</i> Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Emergency surgery: VWF:RCo 50 to 60 units/kg to achieve a target VWF:RCo peak plasma concentration of 100 units/dL; monitor trough coagulation factor levels for subsequent doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nonemergent surgical management: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: Calculate based on patient's baseline and target VWF:RCo and IVR. The IVR (in vivo recovery) ideally should be assessed prior to surgery (eg, previous course of Humate P). If the calculated IVR is not available, assume IVR to be 2 units/dL per unit/kg of VWF:RCo administered. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose (units) = (Target peak VWF:RCo [units/dL] - Baseline VWF:RCo [units/dL]) x weight (kg) / IVR (units/dL per units/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Target peak VWF:RCo plasma concentrations are dependent on surgery type (see below).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Procedure specific target VWF:RCo and FVIII:C plasma concentrations and minimum durations: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Oral surgery (extraction of &le;2 nonmolar teeth with no bony involvement): </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: One-half loading dose every 8 hours as needed to maintain trough VWF:RCo concentration &ge;30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Administer at least one maintenance dose. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Minor surgery: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: One-half loading dose every 8 hours for at least 48 hours to maintain trough VWF:RCo concentration &ge;30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Major surgery/Oral surgery (extraction of &gt;2 teeth or &gt;1 impacted wisdom tooth): </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 100 units/dL and target peak plasma FVIII:C concentration of 80 to 100 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations. </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: One-half loading dose every 8 hours for at least 72 hours to maintain both trough VWF:RCo and FVIII:C concentrations &gt;50 units/dL up to 3 days postsurgery and &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Wilate:</i> Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General dosing recommendations:</i> The in vivo recovery (IVR) should be calculated and baseline plasma VWF:RCo activity should be assessed in all patients prior to surgery. The loading dose may then be calculated using the IVR. If the calculated IVR is not available, assume IVR to be 2 units/dL per unit/kg of VWF:RCo administered. If the calculated IVR is &gt;2.5, assume IVR to be 2.5 units/dL per units/kg of VWF:RCo administered. The formulas to calculate the loading dose is as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose (units) = [(Target peak VWF:RCo [units/dL] - Baseline VWF:RCo [units/dL]) x weight (kg)] / IVR (units/dL per units/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Procedure specific dosing and target VWF:RCo concentrations: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Minor surgery (including tooth extraction):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo 30 to 60 units/kg administered within 3 hours prior to surgery to achieve VWF:RCo peak concentration 50% of normal </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: VWF:RCo 15 to 30 units/kg/dose (or one-half the loading dose) every 12 to 24 hours to maintain VWF:RCo trough concentrations &gt;30% of normal until wound healing is achieved, for up to 3 days. Do not exceed FVIII:C activity concentrations of 250%. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Major surgery: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo 40 to 60 units/kg administered within 3 hours prior to surgery to achieve VWF:RCo peak concentration 100% of normal. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: VWF:RCo 20 to 40 units/kg/dose (or one-half the loading dose) every 12 hours for the first 24 hours after the start of surgery to maintain VWF:RCo trough concentrations &gt;50% of normal; then may adjust to every 12 to 24 hours to maintain VWF:RCo trough concentrations &gt; 50% of normal and continue until wound healing is achieved, up to 6 days or more. Do not exceed FVIII:C activity concentration of 250%. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Factor VIII deficiency: General guidelines (consult specific product labeling for Alphanate or Humate-P):</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment; in general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Minor hemorrhage: Loading dose: FVIII:C 15 units/kg to achieve FVIII:C plasma level ~30% of normal. If second infusion is needed, half the loading dose may be given once or twice daily for 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate hemorrhage: Loading dose: FVIII:C 25 units/kg to achieve FVIII:C plasma level ~50% of normal; Maintenance: FVIII:C 15 units/kg every 8 to 12 hours for 1 to 2 days in order to maintain FVIII:C plasma levels at 30% of normal. Repeat the same dose once or twice daily for up to 7 days or until adequate wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Life-threatening hemorrhage/major surgery: Loading dose: FVIII:C 40 to 50 units/kg; Maintenance: FVIII:C 20 to 25 units/kg every 8 to 12 hours to maintain FVIII:C plasma levels at 80% to 100% of normal for 7 days. Continue same dose once or twice daily for another 7 days in order to maintain FVIII:C levels at 30% to 50% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>von Willebrand disease (VWD); treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humate-P:</i> IV: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment; in general, administration of factor VIII 1 unit/kg would be expected to raise circulating VWF:RCo ~5 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Type 1, mild VWD: Minor hemorrhage (if desmopressin is not appropriate) or major hemorrhage:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo 40 to 60 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: VWF:RCo 40 to 50 units/kg every 8 to 12 hours for 3 days, keeping VWF:RCo nadir &gt;50%; follow with 40 to 50 units/kg daily for up to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Type 1, moderate or severe VWD:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage: VWF:RCo 40 to 50 units/kg for 1 to 2 doses </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major hemorrhage: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: VWF:RCo 50 to 75 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg every 8 to 12 hours for 3 days to keep the VWF:RCo nadir &gt;50%, then 40 to 60 units/kg daily for a total of up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Types 2 and 3 VWD:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage: VWF:RCo 40 to 50 units/kg for 1 to 2 doses </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major hemorrhage:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: VWF:RCo 60 to 80 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg every 8 to 12 hours for 3 days, keeping the VWF:RCo nadir &gt;50%; follow with 40 to 60 units/kg daily for a total of up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Wilate:</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minor hemorrhage:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo: 20 to 40 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 20 to 30 units/kg every 12 to 24 hours for &le;3 days, keeping the VWF:RCo nadir &gt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major hemorrhage:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: VWF:RCo: 40 to 60 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 20 to 40 units/kg every 12 to 24 hours for 5 to 7 days, keeping the VWF:RCo nadir &gt;50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>von Willebrand disease (VWD); prophylaxis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alphanate: Surgery/invasive procedure prophylaxis (except patients with type 3 undergoing major surgery): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preoperative dose: VWF:RCo: 60 units/kg 1 hour prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: VWF:RCo: 40 to 60 units/kg every 8 to 12 hours as clinically needed. For minor procedures, maintain FVIII:C activity level of 40 to 50 units/dL during postoperative days 1 to 3; for major procedures maintain FVIII:C activity level of 100 units/dL for 3 to 7 days. Do not exceed FVIII:C activity level of 150 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humate-P:</i> Surgery/procedure prevention of bleeding: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Emergency surgery: Administer VWF:RCo 50 to 60 units/kg; monitor trough coagulation factor levels for subsequent doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Surgical management (nonemergency):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose calculation based on baseline target VWF:RCo: (Target peak VWF:RCo - Baseline VWF:RCo) x weight (in kg) / IVR = units VWF:RCo required. Administer loading dose 1 to 2 hours prior to surgery. <b>Note:</b> If in vivo recovery (IVR) is not available, assume 2 units/dL per units/kg of VWF:RCo product administered. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Target concentrations for VWF:RCo following loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Major surgery: 100 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Minor surgery: 50 to 60 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: Initial: One-half loading dose, followed by subsequent dosing determined by target trough concentrations, generally every 8 to 12 hours. Patients with shorter half-lives may require dosing every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Target maintenance trough VWF:RCo concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Major surgery: &gt;50 units/dL for up to 3 days, followed by &gt;30 units/dL for a minimum total treatment of 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Minor surgery: &ge;30 units/dL for a minimum duration of 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral surgery: &ge;30 units/dL for a minimum duration of 8 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000423\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [human derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">250 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">500 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1000 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1500 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2000 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 250 units and VWF:RCo 600 units [contains albumin; packaged with diluent] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 500 units and VWF:RCo 1200 units [contains albumin; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 1000 units and VWF:RCo 2400 units [contains albumin; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wilate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 500 units and VWF:RCo 500 units [contains polysorbate 80 (in diluent); packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 1000 units and VWF:RCo 1000 units [contains polysorbate 80 (in diluent); packaged with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000444\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573581\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information\" class=\"drug drug_general\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958737\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Administer through a separate line, do not mix with drugs or other IV fluids. Vasomotor reactions may result from rapid administration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate: Infuse slowly; maximum rate: 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P: Infuse slowly; maximum rate: 4 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wilate: Infuse slowly at a rate of 2 to 4 mL/minute; reduce the rate or interrupt administration in patients who experience a marked increase in pulse rate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000359\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Products are stable for three years, up to the expiration date printed on the label. For single use; discard any unused contents in vial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alphanate: Store intact vials at &le;25&deg;C (&le;77&deg;F); do not freeze. May store reconstituted solution at room temperature (&le;30&deg;C). Use within 3 hours of reconstitution; do not refrigerate after reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Humate-P: Store intact vials at &le;25&deg;C (&le;77&deg;F); do not freeze. Once reconstituted, do not refrigerate and use within 3 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wilate: Store intact vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Store in original container to protect from light. Intact vials may also be stored at room temperature (not to exceed 25&deg;C [77&deg;F]) for &le;6 months. Once stored at room temperature, do not return to the refrigerator. Following reconstitution, use solution immediately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958728\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemophilia A (Factor VIII deficiency): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate: Prevention and treatment of hemorrhagic episodes in hemophilia A (classic hemophilia) (FDA approved in ages &ge;7 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P: Prevention and treatment of hemorrhagic episodes in hemophilia A (classic hemophilia) (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">von Willebrand disease (VWD): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate: Prophylaxis for surgical and/or invasive procedures in patients with VWD when desmopressin is either ineffective or contraindicated [FDA approved in ages &ge;7 years and adults]. <b>Note:</b> Not indicated for patients with severe VWD undergoing major surgery. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P: Treatment of spontaneous and trauma-induced hemorrhagic episodes and prevention of excessive bleeding during and after surgery in patients with mild to moderate and severe VWD where the use of desmopressin is suspected or known to be inadequate (FDA approved in ages &ge;1 month and adults). <b>Note:</b> Not indicated for the prophylaxis of spontaneous bleeding episodes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wilate: On demand treatment and control of bleeding episodes in patients with VWD (FDA approved in ages &ge;5 years and adults); perioperative management of bleeding in patients with VWD (FDA approved in all ages) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595830\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000356\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, facial edema, orthostatic hypotension, peripheral edema, phlebitis, pulmonary embolism (large doses), subdural hematoma, thrombophlebitis, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Cerebral hemorrhage, chills, dizziness, drowsiness, fatigue, headache, insomnia, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypermenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation, gastrointestinal hemorrhage, nausea (postoperative), sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhage (30%; postoperative), anemia, decreased hematocrit (moderate), increased factor VIII inhibitors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection, parvovirus B19 seroconversion (not accompanied by clinical signs of disease), sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, pharyngitis, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever, postoperative pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Antibody development (neutralizing), cardiorespiratory arrest, hemolysis, hypervolemia, parotid gland enlargement, seizure, shock, tachycardia, thromboembolic complications, venous thrombosis (femoral)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000350\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reaction, including anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor or any component of the formulation; hypersensitivity to human plasma derived products (Wilate only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000351\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: Neutralizing antibodies (inhibitors) may develop to factor VIII or von Willebrand factor, particularly in patients with type 3 (severe) von Willebrand disease. Patients who develop antibodies against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity or allergic reactions have been observed, including anaphylaxis and shock (with or without fever). Monitor patients closely during infusion; if allergic symptoms occur, discontinue administration and initiate treatment immediately. Patients experiencing anaphylactic reactions should be evaluated for the presence of inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thromboembolic events have been reported; especially in patients with known risk factors for thrombosis. Risk of thromboembolic events may be increased in female patients, patients with endogenous high concentrations of factor VIII, and in patients who receive continued treatment resulting in an excessive rise in factor VIII activity; monitor concentrations of von Willebrand factor and factor VIII closely. Use with caution and consider antithrombotic measures when treating patients with von Willebrand disease that are at an increased risk for thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vasomotor reactions: Rapid administration may result in vasomotor reactions; do not exceed administration rate recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Products vary by preparation method; some final formulations may contain human albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood types A, B, and AB: Alphanate and Humate-P contain trace amounts of blood groups A and B isohemagglutinins; use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB. Monitor patients for signs of intravascular hemolysis and falling hematocrit; discontinue therapy and consider administration of serologically compatible type O red blood cells if progressive hemolytic anemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Dosage requirements will vary in patients with factor VIII inhibitors; optimal treatment should be determined by the extent of bleeding, presence of inhibitors, and clinical response. Frequency of use is determined by the severity of the disorder or bleeding pattern.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819746\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur, particularly in patients with Type 3 (severe) von Willebrand factor; reported overall incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2 to 7 days, with peak concentrations at 1 to 3 weeks after therapy; children &lt;5 years of age may also be at greatest risk. Patients who develop antibodies (usually antibody concentration &gt;10 Bethesda units/mL) against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298759\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218025\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13397&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000346\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000347\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women with von Willebrand disease have an increased risk of bleeding associated with invasive gynecologic procedures and delivery. The risk of miscarriage is also increased (NHLBI 2007; Pacheco 2010). Pregnant women with von Willebrand disease or hemophilia may have a transient increase in factor VIII during the second and third trimesters. Close monitoring is needed and therapy is recommended if levels are &lt;50 units/dL prior to delivery (Pacheco 2010; Srivastava 2013). If otherwise indicated, therapy with von Willebrand factor concentrates should be used. Bleeding associated with postpartum hemorrhage is increased and may be delayed; women should be monitored after delivery for at least 2 weeks (Pacheco 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958738\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of intravascular hemolysis or bleeding; heart rate and blood pressure (before and during IV administration); hypersensitivity reactions during the infusion. AHF concentrations prior to and during treatment; in patients with circulating inhibitors, the inhibitor concentration should be monitored; hematocrit; VWF activity (circulating concentrations of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]). In surgical patients, monitor VWF:RCo at baseline and after surgery, trough VWF:RCo and FVIII:C at least daily. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3958739\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Hemophilia: Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII:C</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe: Factor level &lt;1% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate: Factor level 1% to 5% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild: Factor level &gt;5% to 30% of normal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000361\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Factor VIII and von Willebrand factor (VWF), obtained from pooled human plasma, are used to replace endogenous factor VIII and VWF in patients with hemophilia or von Willebrand disease. Factor VIII in conjunction with activated factor IX, activates factor X which converts prothrombin to thrombin and fibrinogen to fibrin. VWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII. (Circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000404\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Shortening of bleeding time: Immediate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: von Willebrand disease: Shortening of bleeding time: &lt;6 hours postinfusion; presence of VWF multimers detected in the plasma: &ge;24 hours (Alphanate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: VWF:RCo: Humate: 29 to 290 mL/kg; Wilate: 15 to 160 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Factor VIII coagulant activity (FVIII:C): Range: 8 to 28 hours in patients with hemophilia A</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VWF:RCo: Range (in patients with von Willebrand disease): Alphanate: 4 to 16 hours; Humate: 3 to 34 hours; Wilate: 6 to 49 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4028798\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">One unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Exact potency varies among products and between lots of the same product; each vial contains the exact labeled amount of VWF activity, as measured with the Ristocetin cofactor activity (VWF:RCo), and factor VIII (FVIII) activity and should be consulted prior to use. However, the average ratio between VWF:RCo and FVIII among available products is:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate: Average ratio not provided by manufacturer or in available literature</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P: Average ratio of VWF:RCo to FVIII is 2.4:1</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wilate: Average ratio of VWF:RCo to FVIII is ~1:1</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Formula to calculate specific in vivo recovery (IVR) is as follows:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">IVR (units/dL per units/kg of VWF:RCo administered) = ([Plasma VWF:RCo 30 minutes after infusion (units/dL)] &ndash; [Plasma VWF:RCo at baseline (units/dL)] / Dose (units /kg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121602\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Wilate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-500 unit (1): $1.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-1000 unit (1): $1.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Alphanate/VWF Complex/Human Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Humate-P Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-600 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-1200 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-2400 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24170861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleviate (AU, HK);</li>\n      <li>Alphanate (CL, HK, LK, MY, PH, SG, TH);</li>\n      <li>Biostate (AU, HK, NZ, SG);</li>\n      <li>Haemate (DK, SE);</li>\n      <li>Haemate P (AR, CH, CO, CY, DE, HR, HU, IL, MY, RO, SI, SK);</li>\n      <li>Haemosolvate Factor VIII (ZA);</li>\n      <li>Immunate (TH);</li>\n      <li>Voncento (CZ, DE, EE, FR, GB, IE, PL, PT, SE);</li>\n      <li>Wilate (AU, EE, IE, LT, MX, PL, PT, UY);</li>\n      <li>Wilnativ (DK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alphanate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humate-P (antihemophilic factor/von Willebrand factor complex) [prescribing information]. Kankakee, IL: CSL Behring LLC; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Hemophilia Foundation. MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NHLBI VWD Expert Panel, &quot;The Diagnosis, Evaluation, and Management of von Willebrand Disease. US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute, 2007, NIH No. 08-5832.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information/abstract-text/22776238 /pubmed\" target=\"_blank\" id=\"22776238 \">22776238 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Hoboken, NJ: Octapharm USA Inc; August 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13397 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3000299\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663155\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F3958727\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F3958736\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3000423\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F3000444\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573581\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3958737\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3000359\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3958728\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11595830\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3000356\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3000350\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3000351\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819746\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298759\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218025\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3000346\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3000347\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3958738\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F3958739\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3000361\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F3000404\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F4028798\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121602\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24170861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13397|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information\" class=\"drug drug_general\">Human-plasma derived von Willebrand factor (contains factor VIII): Drug information</a></li><li><a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-patient-drug-information\" class=\"drug drug_patient\">Human-plasma derived von Willebrand factor (contains factor VIII): Patient drug information</a></li></ul></div></div>","javascript":null}